Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tiotropium
Drug ID BADD_D02443
Description Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium].[A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]
Indications and Usage Used in the management of chronic obstructive pulmonary disease (COPD).
Marketing Status Not Available
ATC Code R03BB04
DrugBank ID DB01409
KEGG ID D01929
MeSH ID D000069447
PubChem ID 5487427
TTD Drug ID D0P1WA
NDC Product Code Not Available
Synonyms Tiotropium Bromide | Bromide, Tiotropium | 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane bromide | Tiotropium | Spiriva | BA 679 BR | 679 BR, BA | BR, BA 679 | BA-679 BR | BA679 BR
Chemical Information
Molecular Formula C19H22NO4S2+
CAS Registry Number 186691-13-4
SMILES C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary tract obstruction20.08.01.0040.000243%
Lower limb fracture15.08.03.004; 12.04.01.0040.000243%Not Available
Pulmonary function test abnormal13.19.01.0050.000095%Not Available
Disease progression08.01.03.038--
Drug intolerance08.06.01.013--Not Available
Obstructive airways disorder22.03.01.0110.001339%Not Available
Psychotic disorder19.03.01.002--
Pulmonary function test decreased13.19.01.0010.000730%Not Available
Renal impairment20.01.03.010--Not Available
Respiratory tract infection22.07.07.001; 11.01.08.0170.001095%Not Available
Unevaluable event08.01.03.0510.003529%Not Available
Increased upper airway secretion22.02.05.0210.000852%Not Available
Hyperamylasaemia14.11.01.0030.000487%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.010--Not Available
Blood count abnormal13.01.07.0010.000487%Not Available
Osteonecrosis of jaw24.04.05.005; 15.02.04.010--
Bone marrow failure01.03.03.005--
Treatment failure08.06.01.017--Not Available
Pharyngeal disorder22.04.05.0070.000365%Not Available
Low birth weight baby18.04.02.0030.000608%Not Available
Type 2 diabetes mellitus14.06.01.003; 05.06.01.003--Not Available
Oral disorder07.05.01.0050.000243%Not Available
Oropharyngeal discomfort22.02.05.027; 07.05.05.0080.000365%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.002920%
Acute kidney injury20.01.03.016--
H1N1 influenza11.05.03.002; 22.07.02.0070.000243%Not Available
Foetal growth restriction18.03.01.0020.000608%
Hepatic cancer16.07.02.004; 09.04.02.0080.000063%Not Available
Candida infection11.03.03.0210.001095%
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.0070.000487%Not Available
The 15th Page    First    Pre   15 16    Next   Last    Total 16 Pages